Differences

This shows you the differences between two versions of the page.

--- peter_juni [2022/01/01 10:02]
liam [CBC News]
+++ peter_juni [2022/08/05 04:09] (current)
liam [Abbott Laboratories]
@@ Line 1: / Line 1: @@
 ====== Peter Jüni ======
-{{:sidebar_docs_juni-306x458-c-default.jpeg?150 |}}
+{{ :sidebar_docs_juni-306x458-c-default.jpeg?150|}}
 **Peter Jüni** is a general internist and epidemiologist, and holds a Tier 1 Canada Research Chair in Clinical Epidemiology of Chronic Diseases. He is the Scientific Director of the [[Ontario COVID-19 Science Advisory Table]], and sits on the Drugs & Biologics Clinical Practice Guidelines Working Group.((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved December 31, 2021, from https://covid19-sciencetable.ca/about/#juni-peter))
-He has received funding from a variety of pharmaceutical companies including [[Abbott]] Vascular, [[Amgen]], [[Appili Therapeutics]], [[AstraZeneca]], [[AVA Pharmaceuticals]], [[Biosensors International]], [[Biotronik]], [[Eli Lilly]], [[Fresenius]], [[The Medicines Company]] and [[Terumo]].((Jüni, P. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/08/Declaration-of-Interest_Science-Table_Peter-Juni7_20210702.pdf))
+He has received funding from a variety of pharmaceutical companies including [[pharmaceutical_companies:Abbott]] Vascular, [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Appili Therapeutics]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:AVA Pharmaceuticals]], [[Biosensors International]], [[Biotronik]], [[pharmaceutical_companies:Eli Lilly]], [[Fresenius]], [[The Medicines Company]] and [[Terumo]].((Jüni, P. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/08/Declaration-of-Interest_Science-Table_Peter-Juni7_20210702.pdf))
 ===== Education =====
@@ Line 48: / Line 48: @@
 ==== CanCOVID ====
-Jüni is a Network Science Advisor on the Executive Leadership team of [[CanCOVID]], where he has received funding as as co-principal investigator.((//About.// CanCOVID. Retrieved December 31, 2021, from https://archive.ph/SqnMv))
+Jüni is a Network Science Advisor on the Executive Leadership team of [[CanCOVID]], where he has received funding as a co-principal investigator.((//About.// CanCOVID. Retrieved December 31, 2021, from https://archive.ph/SqnMv))
 ==== The Cochrane Collaboration ====
@@ Line 68: / Line 68: @@
 === St. Michael’s Hospital ===
-Jüni is the Director of the Applied Health Research Centre (AHRC) at the Li Ka Shing Knowledge Institute at [[St. Michael’s Hospital]] under [[Unity Health Toronto]].
+Jüni is the former Director of the Applied Health Research Centre (AHRC) at the [[Li Ka Shing Knowledge Institute]] at [[St. Michael’s Hospital]] under [[Unity Health Toronto]].((//Dr. Peter Jüni.// Critical Care Canada Forum. Retrieved May 14, 2022, from https://criticalcarecanada.com/speaker/dr-peter-juni/))
 ==== University of Bern ====
@@ Line 78: / Line 77: @@
 Jüni is a Professor of Medicine and Epidemiology in the Department of Medicine and Institute of Health Policy, Management and Evaluation at the [[University of Toronto]].
-He received funding from U of T as a Co-Applixant for a study called "Prone positioning for patients on general medical wards with COVID19: A multicenter pragmatic randomized trial."((Unity Health Toronto, Sunnybrook Health Sciences Centre, Sinai Health System, Toronto General Hospital, University Health Network, Toronto, & William Osler Health System. (2021, May 12). //Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE].// ClinicalTrials.gov. https://archive.ph/v6K4Q))
+He received funding from U of T as a Co-Applicant for a study called "Prone positioning for patients on general medical wards with COVID19: A multicenter pragmatic randomized trial."((Unity Health Toronto, Sunnybrook Health Sciences Centre, Sinai Health System, Toronto General Hospital, University Health Network, Toronto, & William Osler Health System. (2021, May 12). //Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE].// ClinicalTrials.gov. https://archive.ph/v6K4Q))
-He is also a Co-Primary Investigator in study called "Control of COVID-19 outbreaks in long term care" funded by a grant from U of T.
+He is also a Co-Primary Investigator in a study called "Control of COVID-19 outbreaks in long term care" funded by a grant from U of T.
 ===== Relationships with Pharmaceutical Companies =====
@@ Line 86: / Line 85: @@
 ==== Abbott Laboratories ====
-Jüni serves as an unpaid member of the steering group or executive committee of trials funded by [[Abbott]] Vascular and [[St. Jude Medical]], which was acquired by Abbott Laboratories in January 2017.((Cortez, M. F. (2016, April 28). //Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion.// Bloomberg. https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion)) ((Wang, D. (2016, April 28). //Abbott-St. Jude Combination: Why It Makes Sense.// Bloomberg Daybreak: Americas. https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense))
+Jüni serves as an unpaid member of the steering group or executive committee of trials funded by [[Abbott]] Vascular and [[St. Jude Medical]], which was acquired by Abbott Laboratories in January 2017.((Cortez, M. F. (2016, April 28). //Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion.// Bloomberg. https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion)) ((Wang, D. (2016, April 28). //Abbott-St. Jude Combination: Why It Makes Sense.// Bloomberg Daybreak: Americas. https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense)) ((Jüni, P. (2021, October 4). //ICMJE Disclosure Form.// BMJ. https://web.archive.org/web/20220805012030/https://www.bmj.com/sites/default/files/attachments/bmj-article/pre-pub-history/coi_disclosure_pj_rapid.pdf))
 ==== Amgen ====
-Jüni is paid honoraria (to his institution) for participation in advisory boards and/or consulting from [[Amgen]], as well as being reimbursed travel/accomodation/meeting expenses.
+Jüni is paid honoraria (to his institution) for participation in advisory boards and/or consulting from [[Amgen]], as well as being reimbursed travel/accommodation/meeting expenses.
 ==== Appili Therapeutics ====
@@ Line 132: / Line 131: @@
 **"Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial"**((//Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care.// (2021, October 26). ClinicalTrials.gov. https://archive.ph/Ea15u)) ((Sholzberg, M., Tang, G. H., Negri, E., Rahhal, H., Kreuziger, L. B., Pompilio, C. E., James, P., Fralick, M., AlHamzah, M., Alomran, F., Tseng, E., Lim, G., Lillicrap, D., Carrier, M., Áinle, F. N., Beckett, A., da Costa, B. R., Thorpe, K., Middeldorp, S., & Lee, A. (2021). //Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.// Trials, 22(1), 202. https://doi.org/10.1186/s13063-021-05076-0))
-Funded by [[Defense Research Development Canada]] under the [[Department of National Defense]], [[St. Michael’s Hospital Foundation]], St. Joseph’s Health Centre Foundation]], and the [[International Network of Venous Thromboembolism Clinical Research Networks]] (INVENT) Kickstarter Award.
+Funded by [[Defense Research Development Canada]] under the [[Department of National Defense]], [[St. Michael’s Hospital Foundation]], [[St. Joseph’s Health Centre Foundation]], and the [[International Network of Venous Thromboembolism Clinical Research Networks]] (INVENT) Kickstarter Award.
+**"Cash transfer during the COVID-19 pandemic: a multicentre, randomised controlled trial"**
+Conclusions: "A single cash transfer did not reduce the COVID-19 symptoms or improve the ability to afford necessities. Further studies are needed to determine whether some groups may benefit from financial supports and to determine if a higher level of support is beneficial."((Persaud, N., Thorpe, K. E., Bedard, M., Hwang, S. W., Pinto, A., Jüni, P., & da Costa, B. R. (2021). //Cash transfer during the COVID-19 pandemic: a multicentre, randomised controlled trial.// Family Medicine and Community Health, 9(4), e001452. https://doi.org/10.1136/fmch-2021-001452))
+**"Risk-stratification of febrile African children at risk of sepsis using sTREM-1 as basis for a rapid triage test"**
+Funded by the [[Bill & Melinda Gates Foundation]], [[Intellectual Ventures]], the [[Canadian Institutes of Health Research]] (CIHR), [[Canada Research Chair Program]] (CRCP), and donations from [[Kim Kertland]] and the [[Tesari Foundation]].((Leligdowicz, A., Conroy, A. L., Hawkes, M., Richard-Greenblatt, M., Zhong, K., Opoka, R. O., Namasopo, S., Bell, D., Liles, W. C., da Costa, B. R., Jüni, P., & Kain, K. C. (2021). //Risk-stratification of febrile African children at risk of sepsis using sTREM-1 as basis for a rapid triage test.// Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-27215-6))
+**"Age and Sex Specific Prevalence of Clinical and Screen-Detected Atrial Fibrillation in Hospitalized Patients"**
+Funded by the [[Swiss National Science Foundation]] and the [[Swiss Heart Foundation]].((Roten, L., Goulouti, E., Lam, A., Elchinova, E., Nozica, N., Spirito, A., Wittmer, S., Branca, M., Servatius, H., Noti, F., Seiler, J., Baldinger, S. H., Haeberlin, A., de Marchi, S., Asatryan, B., Rodondi, N., Donzé, J., Aujesky, D., Tanner, H., & Reichlin, T. (2021). //Age and Sex Specific Prevalence of Clinical and Screen-Detected Atrial Fibrillation in Hospitalized Patients.// Journal of Clinical Medicine, 10(21), 4871. https://doi.org/10.3390/jcm10214871))
+Jüni was a co-investigator on a study titled “From idea to reality: COVID-19 Vaccination for Children and Youth” taking place from June 1, 2021 to May 31, 2022. It was funded by the [[Canadian Institutes of Health Research]] through an “Emerging COVID-19 Research Gaps and Priorities - Vaccines” operating grant.((//From idea to reality: COVID-19 Vaccination for Children and Youth.// (2021, June 1). Canadian Research Information System. https://archive.ph/RsJVt)) The intended outcome of the study is to examine vaccine safety and efficacy of [[COVID-19 vaccines]] in children and youth, to provide confidence to parents considering vaccinating their children, and increase [[vaccine hesitancy|vaccine uptake]].((Wyse, M. (2021). //Pediatric Studies.// [[COVID-19 Immunity Task Force]]. https://web.archive.org/web/20220514231409/https://www.covid19immunitytaskforce.ca/task-force-research/pediatric/))
 ===== Media Appearances =====
@@ Line 142: / Line 154: @@
 ==== CTV News ====
-  * December 12, 2021: Jüni encouraged Ontarians to get a "booster dose" of a [[COVID-19_Vaccine]] product due to the rapid spread of the Omicron variant of [[SARS-CoV-2]]. "If you're fully vaccinated - two doses, this doesn't protect you anymore against infection, that's a reality. But it continues to prevent serious disease, that's most likely the case based on everything we know." He also stated that he would bet on the definition of "fully vaccinated" being changed shortly, "because to be honest if you have two doses and go into a restaurant you're able to infect the entire restaurant."((Pringle, J. (2021, December 12). //“We really need optimal protection”: Head of COVID-19 science table urges everyone to get COVID-19 booster shot.// CTV News Ottawa. https://archive.ph/0TTli))
+  * December 12, 2021: Jüni encouraged Ontarians to get a "booster dose" of a COVID-19 vaccine product due to the rapid spread of the Omicron variant of [[SARS-CoV-2]]. "If you're fully vaccinated - two doses, this doesn't protect you anymore against infection, that's a reality. But it continues to prevent serious disease, that's most likely the case based on everything we know." He also stated that he would bet on the definition of "fully vaccinated" being changed shortly, "because to be honest if you have two doses and go into a restaurant you're able to infect the entire restaurant."((Pringle, J. (2021, December 12). //“We really need optimal protection”: Head of COVID-19 science table urges everyone to get COVID-19 booster shot.// CTV News Ottawa. https://archive.ph/0TTli))
 ==== Interaction 19 Conference ====
 Jüni was paid to speak on the topic of "clinical research" at [[Interaction Design Association|Interaction 19 Conference]], an event held in early February 2019 in Seattle, Washington and sponsored by [[Adobe]], [[Amazon]], [[Google]], [[Microsoft]], [[Facebook]], [[Cisco]], [[Netflix]], [[Oracle]], [[Salesforce]], [[Spotify]], [[Squarespace]], [[Twitter]], [[Verizon]], [[Volvo]] and [[Westin]], among others.((//Interaction 19 – 3-8 February 2019 • Seattle, WA.// Interaction Design Association. Retrieved December 31, 2021, from https://interaction19.ixda.org/)) ((//Our Partners.// Interaction Design Association. Retrieved December 31, 2021, from https://interaction19.ixda.org/partners/))